-
Thalidomide-rituximab was administered to 25 symptomatic patients (20 previously untreated) with Waldenstrom macroglobulinemia. The overall response rate was 72%, and the median time-to-progression for responders was 38 months.
-
The role of bisphosphonates in the treatment and prevention of bone metastases remains incompletely characterized. In the current report, Diel et al detail long-term survival data on patients with known microscopic bone disease more than eight years after adjuvant treatment with clodronate.
-
The risk of recurrent venous thromboembolism (VTE) during extended anticoagulant therapy for thrombophilia remains poorly defined. Investigators analyzed 661 patients with idiopathic VTE who had been randomized to extended prophylaxis after three months of initial anticoagulation using either low intensity (INR 1.5-1.9) or standard intensity (INR 2.0-3.0) anticoagulation.
-
-
The largest patient "look-back" notification in medical history involving some 40,000 patients potentially exposed to hepatitis C, HBV, and HIV in a Las Vegas endoscopy clinic allegedly was driven by policies designed to save money and carried out by medical staff who should have known they were putting patients at risk, Hospital Infection Control has learned.
-
In this issue: The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
A large prospective cohort study of perineal talc use demonstrated no increased risk of ovarian cancer overall or within any histological subtype. In addition, no association with talc application method was observed.
-
According to this pharmacokinetic study, the cyclic use of 20 mcg ethinyl estradiol oral contraceptives is problematic for obese women. Ovarian activity was better suppressed with continuous use (omitting the hormone-free interval) of the same dose oral contraceptive or increasing to a higher dose 30 mcg ethinyl estradiol oral contraceptive
-
Polycystic ovarian syndrome patients with normospermic partners undergoing ovulation induction with letrozole had a higher live birth rate and no increase in adverse outcomes than women who received clomiphene citrate.
-
Venous thromboembolism (VTE) is the third most common cardiovascular condition behind myocardial infarction and stroke, with an incidence rate of about one per 1000 person-years.1,2 Nearly 5% of the population will experience